Exicure, Inc. reported a net loss of $4.9 million for the fiscal year ending December 31, 2025, a significant improvement compared to a net loss of $9.7 million in 2024. The company did not generate any revenue in 2025, a decrease from $500,000 in the previous year, primarily due to the cessation of its research and development activities. Total operating expenses for 2025 were $4.2 million, down 67% from $12.7 million in 2024, reflecting a halt in R&D spending and a reduction in general and administrative costs. The company’s accumulated deficit now stands at $223 million.
In terms of strategic developments, Exicure has been actively exploring alternatives to maximize shareholder value. In January 2025, the company acquired GPCR Therapeutics USA Inc. and entered into a License and Collaboration Agreement to develop GPCR's technologies. This acquisition is expected to involve milestone payments and royalties, although the exact financial impact remains uncertain. Additionally, Exicure formed a wholly-owned subsidiary in South Korea, KC Creation, in March 2025, but decided to sell it in November 2025 as part of its strategic realignment.
Operationally, Exicure's workforce has been reduced to eight full-time employees as of December 31, 2025, following significant layoffs in 2022. The company has also faced challenges in maintaining compliance with Nasdaq listing requirements, having received multiple deficiency notices in the past year. As of March 17, 2026, Exicure's common stock was trading at $4.54 per share, with HiTron Inc. owning approximately 25% of the outstanding shares, which may influence future corporate governance and strategic decisions.
Looking ahead, Exicure's management has expressed substantial doubt about the company's ability to continue as a going concern without additional financing. The company reported cash and cash equivalents of approximately $3.7 million as of December 31, 2025, which is insufficient to cover its operational needs for the next 12 months. Exicure plans to seek further capital through equity offerings and strategic partnerships, but the current market conditions and the company's transitional state may hinder these efforts. The management's ability to execute its strategic plan will be critical in determining the company's future viability.
About EXICURE, INC.
Exicure, Inc. is a biotechnology company focused on developing nucleic acid therapies targeting RNA. It has historically worked on spherical nucleic acid (SNA) technology for therapeutic applications but has shifted to exploring strategic transactions and asset sales. The company owns a patent portfolio, engages in licensing, and seeks growth through acquisitions and partnerships, primarily in Asia, with no current revenue stream or manufacturing operations.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.